News & Events about Lianbio.
Globe Newswire
3 months ago
SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following ...
I-Mab (NASDAQ:IMAB Get Rating) and LianBio (NASDAQ:LIAN Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and ...
Ticker Report
8 months ago
LianBio (NASDAQ:LIAN Get Rating) Director Perceptive Advisors Llc acquired 120,000 shares of the firms stock in a transaction that occurred on Wednesday, May 25th. The shares were purchased at an average cost of $2.63 per share, for a total transaction of $315,600.00. Following the ...
Thinking about buying stock in LianBio, BioSig Technologies, Nordstrom, Apyx Medical, or Bloomin' Brands? Thinking about buying stock in LianBio, BioSig Technologies, Nordstrom, Apyx Medical, or Bloomin' Brands? PR Newswire NEW YORK, May 26, 2022 NEW YORK, May 26, 2022 /PRNewswire...
Globe Newswire
9 months ago
LianBios partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM ongoingLianBios partner, ...